ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
1,34%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
84,885
-0,14%
Bitcoin
64 756,46
-0,10%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) Actualités

BBIO BridgeBio Pharma Inc

26,60
-1,01 (-3,66%)
21 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
BridgeBio Pharma Inc BBIO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-1,01 -3,66% 26,60 01:53:37
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
27,36 26,89 27,59 27,05 27,61
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/6/202413:30GLOBEBridgeBio Pharma Surpasses Interim Analysis Enrollment..
10/6/202413:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
06/6/202413:30GLOBEBridgeBio Pharma to Participate in the 45th Annual Goldman..
06/6/202412:01EDGAR2Form 8-K - Current report
04/6/202413:30GLOBEBridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5..
03/6/202422:01GLOBEBridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5..
29/5/202422:01GLOBEAdditional Data Showing Acoramidis Increases Serum..
24/5/202413:30GLOBEBridgeBio Pharma to Present Additional Analyses from the..
17/5/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202413:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
14/5/202413:30GLOBEBridgeBio Pharma to Participate in the Bank of America..
13/5/202413:30GLOBEBridgeBio Pharma Presents Additional Data and Analyses from..
02/5/202413:30GLOBEBridgeBio Pharma Reports First Quarter 2024 Financial..
02/5/202413:00GLOBEBridgeBio launches BridgeBio Oncology Therapeutics (BBOT)..
10/4/202413:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
07/4/202419:15GLOBEBridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR)..
20/3/202412:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
06/3/202423:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/3/202423:13EDGAR2Form 8-K - Current report
06/3/202405:53GLOBEBridgeBio Pharma Announces Pricing of Public Offering of..
04/3/202423:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202422:17GLOBEBridgeBio Pharma Announces Proposed Public Offering of..
04/3/202413:00EDGAR2Form 8-K - Current report
04/3/202408:30GLOBEBridgeBio Pharma and Bayer Announce European Licensing..
22/2/202422:27EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202413:31EDGAR2Form 8-K - Current report
22/2/202413:30GLOBEBridgeBio Pharma Reports Fourth Quarter and Full Year 2023..
21/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:06EDGAR2Form 144 - Report of proposed sale of securities
13/2/202422:05EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
13/2/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202413:34GLOBEBridgeBio Pharma and Kyowa Kirin Announce Partnership with..
06/2/202413:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
05/2/202413:30GLOBEBridgeBio Pharma Announces U.S. Food and Drug Administration..
02/2/202413:00GLOBEBridgeBio Pharma Shares Positive Results of Single-Arm Phase..
30/1/202413:00PRNUSInvitae Partners with BridgeBio Pharma to Harness Genetic..
18/1/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202413:30EDGAR2Form 8-K - Current report
18/1/202413:00GLOBEBridgeBio Pharma Secures up to $1.25 Billion of Capital from..
16/1/202422:04EDGAR2Form 144 - Report of proposed sale of securities
10/1/202423:15GLOBEBridgeBio Pharma Announces Publication of Positive Results..
10/1/202413:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
08/1/202423:14EDGAR2Form 8-K - Current report
05/1/202422:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/1/202422:30GLOBEBridgeBio Pharma to Participate in the J.P. Morgan..
03/1/202413:30GLOBEBridgeBio announces FDA clearance of IND application for..
19/12/202322:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202322:13EDGAR2Form 144 - Report of proposed sale of securities
13/12/202313:30GLOBEBridgeBio Announces First Child Dosed in PROPEL 3, its Phase..

Dernières Valeurs Consultées

NASDAQ
BBIO
BridgeBio Pharma
COIN
FINUST
DeFiner
USOTC
TRLM
Truleum (PK)
BIT
P1YEW7
NLBNPIT1YEW7 20241220 420
TG
26O0
Global Uranium and Enric...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés